HKPD (Cellyan Biotechnology Co) Other Current Receivables: $0.01 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKPD Cellyan Biotechnology Co Ltd HKPD
21 GF Score
Price $0.43
! 2 Warning Signs
View Full Analysis

What is Cellyan Biotechnology Co Other Current Receivables?

Cellyan Biotechnology Co HKPD -2.82% 21 Other Current Receivables is $0.01 Mil as of Sep. 2025. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Cellyan Biotechnology Co's Other Current Receivables for the quarter that ended in Sep. 2025 was $0.01 Mil.

Cellyan Biotechnology Co's quarterly Other Current Receivables increased from Sep. 2024 ($0.01 Mil) to Mar. 2025 ($0.06 Mil) but then stayed the same from Mar. 2025 ($0.06 Mil) to Sep. 2025 ($0.01 Mil).

Cellyan Biotechnology Co's annual Other Current Receivables declined from Mar. 2023 ($0.08 Mil) to Mar. 2024 ($0.02 Mil) but then increased from Mar. 2024 ($0.02 Mil) to Mar. 2025 ($0.06 Mil).

Cellyan Biotechnology Co Other Current Receivables Related Terms

Cellyan Biotechnology Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Cellyan Biotechnology Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellyan Biotechnology Co Other Current Receivables Chart

Cellyan Biotechnology Co Annual Data
Trend Mar23 Mar24 Mar25
Other Current Receivables
0.08 0.02 0.06

Cellyan Biotechnology Co Semi-Annual Data
Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Other Current Receivables Get a 7-Day Free Trial 0.00 0.02 0.01 0.06 0.01
HKPD
21GF Score
Cellyan Biotechnology Co Ltd HKPD
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellyan Biotechnology Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.01 Mil mean?
Cellyan Biotechnology Co (HKPD) has a Other Current Receivables of $0.01 Mil as of Sep. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cellyan Biotechnology Co and its competitors.
Is Cellyan Biotechnology Co's Other Current Receivables too high?
Cellyan Biotechnology Co's current Other Current Receivables is $0.01 Mil. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Other Current Receivables compare to COSM and SNYR?
Cellyan Biotechnology Co's Other Current Receivables of $0.01 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Distribution company?
A good Other Current Receivables depends on the Medical Distribution industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current Other Current Receivables is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Other Current Receivables of $0.01 Mil. The current Other Current Receivables is $0.01 Mil. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Other Current Receivables is $0.01 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellyan Biotechnology Co Business Description

Address 13 Ko Fai Road, Room B1, 5th Floor, Well Town Industrial Building, Yau Tong, Kowloon, Hong Kong, HKG
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score

Get the complete analysis for HKPD

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price